<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590679</url>
  </required_header>
  <id_info>
    <org_study_id>PPVI-2013</org_study_id>
    <nct_id>NCT02590679</nct_id>
  </id_info>
  <brief_title>Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p</brief_title>
  <acronym>Venus-P</acronym>
  <official_title>Multi-center Trial of Percutaneous Pulmonary Valve Implantation Using Venus-P Valve for Patients With Severe Pulmonary Regurgitation and Native Right Ventricular Outflow Tract After Previous Surgical Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huaxi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venus-P Valve (Venus Medtech, Shanghai, China) is the first self-expandable interventional
      Pulmonary Valve, which is composed of a Nitinol multilevel support frame with a tri-leaflet
      porcine pericardial tissue valve, and a 14-22 Fr delivery catheter. The purpose of the
      multi-center trial is to evaluate the safety and efficacy of the Venus-P Valve for
      percutaneous pulmonary valve implantation (PPVI) in patients pulmonary regurgitation and
      native right ventricular outflow tract (RVOT) after surgical repair of RVOT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical experience to date with transcatheter pulmonary valve replacement has been limited
      to two balloon expandable systems, namely the Melody Valve (Medtronic Inc, Minneapolis, MN)
      and the Sapien valve (Edwards Lifesciences, Irvine, CA). Both valves have undergone clinical
      trials with good medium-term valve durability. Although both the Melody and the Sapien valves
      have been used in native outflow tracts with good success , limitations to the extended
      application of these valves have generally centered on the maximum diameter of the RVOT.
      Indeed in the majority of patients requiring pulmonary valve replacement (PVR), these balloon
      expandable systems are not large enough to maintain stable valve position within the dilated
      native RVOT.Therefore more recent efforts have concentrated on a self-expanding system to
      provide valve competence despite significant dilation of the native RVOT.

      Venus-P Valve (Venus Medtech, Shanghai, China) is the first self-expandable interventional
      Pulmonary Valve, which is composed of a Nitinol multilevel support frame with a tri-leaflet
      porcine pericardial tissue valve, and a 14-22 Fr delivery catheter. The purpose of the trial
      is to evaluate the safety and efficacy of the Venus-P Valve for PPVI in patients pulmonary
      regurgitation and native RVOT after surgical repair of RVOT.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>right ventricular end diastolic volume index</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse cardiovascular events</measure>
    <time_frame>48 hours</time_frame>
    <description>death, severe arrhythmia, pericardial tamponade, emergency surgery, RVOT rupture, pulmonary artery perforation, cardiac shock, endocarditis, bleeding , and other complications caused by procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths or strokes</measure>
    <time_frame>12 months</time_frame>
    <description>All cause deaths (cardiac death, and non cardiac death) or strokes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary pressure gradient</measure>
    <time_frame>1,3,6,12 months</time_frame>
    <description>Max pressure gradient (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade of pulmonary regurgitation</measure>
    <time_frame>1,3,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class</measure>
    <time_frame>1,3,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk distance</measure>
    <time_frame>1,3,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pulmonary Regurgitation</condition>
  <condition>Tetralogy of Fallot</condition>
  <arm_group>
    <arm_group_label>PRAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venues-P Valve</intervention_name>
    <description>a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract</description>
    <arm_group_label>PRAS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Moderate to severe pulmonary regurgitation after surgical repair of congenital right
             ventricular outflow tract obstruction with trans-annulus or RVOT patch;

          2. right ventricular diastolic volume index: 130-160 mL/m2 measured by isotopic
             examination or cardiac MRI measurements;

          3. Age: ≥10 years and ≤60 years;

          4. Weight ≥18 Kg;

          5. Pulmonary annulus : 14- 31 mm;

          6. RVOT length ≥20mm ;

          7. Signing the informed consent;

          8. Any of the following conditions: ① symptomatic, ②progressive RV systolic dysfunction,
             ③ progressive tricuspid regurgitation (at least moderate), ④ RVOT obstruction with RV
             systolic pressure ≥80 mmHg, ⑤ Sustained atrial/ventricular arrhythmias.

        Exclusion Criteria:

          1. Pre-existing pulmonary artery stenosis or artificial pulmonary valve at any position;

          2. Severe chest wall deformity (funnel chest, etc.);

          3. Acute uncompensated heart failure;

          4. Active infection or endocarditis requiring antibiotic therapy;

          5. Leukopenia (white blood cell &lt;3000 mm3);

          6. Acute or chronic anemia (hemoglobin &lt;9 g/L);

          7. Platelet counts &lt;10000 /mm3;

          8. Impossibly of delivering Venus-P to RVOT as judged by researcher s before procedure;

          9. Known allergy to aspirin or heparin;

         10. Positive urine or serum pregnancy test in female subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenzhi Pan, M.D.</last_name>
    <email>peden@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hopital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenzhi Pan, M.D.</last_name>
      <email>peden@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gejun Zhang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Pan, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Cao QL, Kenny D, Zhou D, Pan W, Guan L, Ge J, Hijazi ZM. Early clinical experience with a novel self-expanding percutaneous stent-valve in the native right ventricular outflow tract. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1131-7. doi: 10.1002/ccd.25544. Epub 2014 May 28.</citation>
    <PMID>24824357</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

